FOXO1, AdipoR Signaling, and JAK/STAT3-Driven Renal Fibrosis: Molecular Nodes of a Unified Neuroendocrine–Metabolic Axis in Type 2 Diabetes Mellitus
Keywords:
FOXO1, AdipoR1/R2, AMPK, JAK/STAT3, hepatic gluconeogenesis, diabetic nephropathy, GLP-1, molecular convergence nodes, adiponectin, renal fibrosis.Abstract
Adipokine imbalance, increasing renal fibrosis, and dysregulated hepatic gluconeogenesis are three interrelated pillars of Type 2 Diabetes Mellitus (T2DM) pathogenesis. Common signaling nodes, such as FOXO1, AdipoR1/R2, and JAK/STAT3, that are researched separately but seldom taken into account within a cohesive mechanistic framework, are shared by the molecular mechanisms coordinating these events. The molecular biology of FOXO1-driven hepatic gluconeogenesis, GLP-1-mediated cAMP/PKA regulation of gluconeogenic programs, AdipoR-mediated AMPK activation in insulin sensitization, and JAK/STAT3 propagation of diabetic nephropathy are the topics of this review. We present a new idea called Molecular Convergence Nodes (MCNs), which are druggable intersections where several disease pathways converge and where pharmacological intervention may result in increased therapeutic effect. In conclusion, FOXO1, AdipoR, and STAT3 are actionable MCNs whose combined targeting may more successfully disrupt the pathological reinforcement loops of type 2 diabetes than existing single-target approaches. We present a research plan for the future that focuses on combination pharmacotherapy and MCN-based biomarker identification.
References
1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806.
2. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
3. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325-338.
4. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12(3):141-151.
5. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85-96.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
7. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107.
8. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-188.
9. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.
10. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117(4):421-426.
11. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17(2):185-196.
12. Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. Diabetologia. 2016;59(8):1624-1627.
13. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466-2472.
14. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117(4):421-426.
15. Nakae J, Oki M, Cao Y. The FoxO transcription factors and metabolic regulation. FEBS Lett. 2008;582(1):54-67.
16. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 2007;6(3):208-216.
17. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction. Nature. 2003;423(6939):550-555.
18. Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes cytoplasmic sequestration of FKHR1. Proc Natl Acad Sci U S A. 1999;96(13):7421-7426.
19. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85-96.
20. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868.
21. Gross DN, van den Heuvel APJ, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene. 2008;27(16):2320-2336.
22. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7(2):95-96.
23. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-871.
24. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84-91.
25. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, et al. Inhibition of PKCε prevents hepatic insulin resistance. Cell Metab. 2007;6(6):476-485.
26. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease. Nat Rev Endocrinol. 2008;4(11):589-598.
27. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171-176.
28. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt. Cell Metab. 2012;15(5):725-738.
29. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457-461.
30. Matsumoto M, Han S, Kitamura T, Accili D. Dual role of FoxO1 in the regulation of hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116(9):2464-2472.
31. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
32. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide-1 (GLP-1). Mol Metab. 2019;30:72-130.
33. Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in pancreatic beta cells. Diabetes. 2004;53(1):5-13.
34. Screaton RA, Conkright MD, Katoh Y, Best JL, Canettieri G, Jeffries S, et al. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004;119(1):61-74.
35. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature. 2007;449(7160):366-369.
36. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes. 2008;57(8):2046-2054.
37. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, et al. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes. 2008;57(10):2603-2612.
38. Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab. 2010;36(Suppl 3):S54-S58.
39. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.
40. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.
41. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-769.
42. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516-523.
43. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab. 2009;296(1):E22-E36.
44. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332-339.
45. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.
46. Sharma K. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5):1645-1656.
47. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin receptor agonist and healthy life extension. Nature. 2013;503(7477):493-499.
48. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. Annu Rev Nutr. 2014;34:31-55.
49. Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, et al. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCζ signaling pathway. Mol Endocrinol. 2011;25(10):1773-1785.
50. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
51. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009;196(1):65-80.
52. Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism. J Clin Invest. 2009;119(6):1438-1449.
53. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056-1060.
54. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev. 2010;31(3):364-395.
55. Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291-312.
56. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025-1078.
57. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5):1645-1656.
58. Rutkowski JM, Wang ZV, Park AS, Zhang J, Zhang D, Hu MC, et al. Adiponectin promotes functional recovery after podocyte injury. Am J Physiol Renal Physiol. 2013;305(11):F1544-F1555.
59. Fang F, Bae EH, Hu A, Liu GC, Zhou X, Williams V, et al. Deletion of the gene for adiponectin accelerates diabetic nephropathy in mice. Am J Physiol Renal Physiol. 2015;308(11):F1318-F1327.
60. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292(2):F617-F627.
61. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-451.
62. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased serum adiponectin levels in patients with type 2 diabetes after SGLT2 inhibitor treatment. J Clin Med Res. 2016;8(4):265-270.
63. Okada-Iwabu M, Iwabu M, Ueki K, Yamauchi T, Kadowaki T. Perspective of small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Diabetes Obes Metab. 2015;17(Suppl 1):74-79.
64. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(Suppl):S121-S131.
65. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281-1283.
66. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-662.
67. Brosius FC III. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord. 2008;9(4):245-254.
68. Lu TC, Wang Z, Feng X, Chuang PY, Fang W, Shen Y, et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 2009;76(1):63-71.
69. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Biol Chem. 2010;285(51):40163-40172.
70. Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes. 2005;54(2):311-321.
71. Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101-108.
72. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433-442.
73. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342-348.
74. Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med. 2013;64:357-366.
75. Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Wang X. STAT3 signaling pathway in podocyte apoptosis. Am J Nephrol. 2012;36(2):121-130.
76. He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, Iyengar R, et al. Nox4 mediates TGF-β1-induced podocyte apoptosis. J Am Soc Nephrol. 2004;15(7):1691-1702.
77. Dryer SE, Reiser J. TRPC6 channels and kidney disease. Physiology (Bethesda). 2010;25(4):229-240.
78. Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol. 2004;15(Suppl 1):S55-S57.
79. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006;151:175-183.
80. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, et al. Leptin stimulates proliferation and TGF-β expression in renal glomerular endothelial cells. Kidney Int. 1999;56(3):860-872.
81. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991-1006.
82. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest. 2004;34(12):785-796.
83. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684-696.
84. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429-1437.
85. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112(12):1776-1784.
86. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327-340.
87. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-823.
88. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83(11):876-886.
89. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949-955.
90. Tuttle KR. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 2005;16(6):1537-1538.
91. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68.
92. Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110-1111.
93. Loscalzo J, Kohane I, Barabási AL. Human disease classification in the postgenomic era. Mol Syst Biol. 2007;3:124.
94. Berger SI, Ma’ayan A, Iyengar R. Systems pharmacology of arrhythmias. Sci Signal. 2010;3(118):ra30.
95. Kitamura T. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol. 2013;9(10):615-623.
96. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep. 2009;9(3):208-214.
97. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab. 2014;28(1):15-23.
98. Banes-Berceli AK, Al-Azawi H, Proctor D, et al. Angiotensin II and JAK/STAT signaling in diabetic nephropathy. Kidney Int. 2007;72(10):1199-1208.
99. Kitada M, Koya D. Renal protective effects of metformin through AMPK activation. Clin Exp Nephrol. 2013;17(4):469-473.
100. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437(7062):1109–1111.
101. Fan W, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ, et al. FOXO1 transrepresses PPARγ transactivation. Cell Metab. 2009;10(6):516–522.
102. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, et al. Role of STAT3 in adiponectin receptor regulation and insulin resistance. J Biol Chem. 2004;279(12):11321–11326.
103. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585.
104. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–966.
105. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub. Nat Med. 2017;23(4):405–408.
106. Pearson ER. Personalized medicine in diabetes: the role of biomarkers. Diabetologia. 2019;62(11):1905–1911.
107. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC. Contributions of gluconeogenesis to glucose production in type 2 diabetes mellitus. J Clin Invest. 1996;98(2):378–385.
108. Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, et al. Biomarkers of diabetic kidney disease. Diabetologia. 2015;58(8):1664–1674.
109. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23(3):85–97.
110. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503(7477):493–499.
111. Wilding JPH. The role of GLP-1 receptor agonists in obesity and diabetes treatment. Lancet Diabetes Endocrinol. 2021;9(11):734–746.
112. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662.
113. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293.
114. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
115. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507–522.
116. Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–1044.
117. Kitada M, Ogura Y, Monno I, Koya D. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function. Front Endocrinol (Lausanne). 2019;10:187.
118. Sun X, He Y, Ma TT, Huang C, Zhang L, Li J. DNMT3a-mediated epigenetic regulation in metabolic disease. Front Cell Dev Biol. 2021;9:645366.
119. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015;58(3):443–455.
120. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528.
121. Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–471.
122. Barabási AL. Network medicine—from obesity to the diseasome. N Engl J Med. 2007;357(4):404–407.
123. Loscalzo J, Barabási AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med. 2011;3(6):619–627.
124. Accili D. Insulin action research and the future of diabetes treatment: the 2017 Banting Medal for Scientific Achievement Lecture. Diabetes. 2018;67(9):1701–1709.
125. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30.
126. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223.
127. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T. Adiponectin receptors and obesity. Handb Exp Pharmacol. 2019;251:47–75.
128. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes. Lancet. 2019;393(10166):31–39.
129. Tuttle KR, Brosius FC, Adler SG, Kretzler M, Mehta RL, Tumlin JA, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease. Nephrol Dial Transplant. 2018;33(11):1950–1959.
130. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, et al. Suppressors of cytokine signaling in diabetic nephropathy. J Am Soc Nephrol. 2010;21(5):763–772.
131. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–1023.
132. Fan W, Morinaga H, Kim JJ, Bae E, Spann NJ, Heinz S, et al. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J. 2010;29(24):4223–4236.
133. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–783.
134. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–692.
135. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666):2011–2015.
136. Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H, et al. Epigenetic regulation of genes involved in insulin secretion and action. Diabetes. 2008;57(5):1149–1154.
137. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol. 2010;299(1):F14–F25.
138. Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653.
139. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–1576.
140. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
141. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184–187.
142. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.
143. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes. Lancet. 2014;383(9922):1068–1083.
144. Forbes JM, Thorburn DR. Mitochondrial dysfunction and diabetic complications. Nat Rev Endocrinol. 2018;14(5):291–312.
145. Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313(21):2119–2120.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Copyright © ANVA Publishing. All rights reserved. Authors retain responsibility for the content of their published work. By submitting and publishing in ANVA Biologica, authors grant ANVA Publishing the right to publish, distribute, archive, and preserve the work in electronic and other formats. No part of this publication may be reproduced, stored, or transmitted without appropriate acknowledgment of the original source and publisher, except as permitted under the journal's licensing terms.
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in ANVA Biologica are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License.
This license permits unrestricted use, distribution, reproduction, adaptation, and sharing of the published work in any medium or format, provided the original author(s) and source are appropriately credited, a link to the license is provided, and any changes made are indicated.
Authors retain copyright of their work while granting ANVA Publishing the right to publish, distribute, archive, and preserve the article as part of the journal record.
To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0/
